UCL 1684 (dibromide)

[1]Burashnikov A, et al. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. J Cardiovasc Pharmacol. 2020;76 (2) :164-172.|[2]Rosa JC, et al. Bis-quinolinium cyclophanes: 6,10-diaza-3 (1,3),8 (1,4) -dibenzena-1,5 (1,4) - diquinolinacyclodecaphane (UCL 1684), the first nanomolar, non-peptidic blocker of the apamin-sensitive Ca (2+) -activated K+ channel. J Med Chem. 1998;41 (1) :2-5.|[3]Diness JG, et al. Effects on atrial fibrillation in aged hypertensive rats by Ca (2+) -activated K (+) channel inhibition. Hypertension. 2011;57 (6) :1129-1135.